Innovative tools and bioactive reagents

Search documents
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
Prnewswire· 2025-07-17 11:00
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir ...
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference
Prnewswire· 2025-05-08 11:00
Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people worldwide [2] Upcoming Events - Kim Kelderman, President and CEO of Bio-Techne, will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 10:40 a.m. PDT [1]
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
Prnewswire· 2025-05-07 10:30
Core Points - Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended March 31, 2025, payable on May 30, 2025, to shareholders of record on May 19, 2025 [1] - The company has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock, starting May 8, 2025, replacing the previous program [2] - Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally [3] Dividend Information - The quarterly dividend is set at $0.08 per share for the quarter ended March 31, 2025 [1] - The dividend payment date is May 30, 2025, with a record date of May 19, 2025 [1] Share Repurchase Program - The new share repurchase program allows for the repurchase of up to $500 million of common stock [2] - The program's execution will depend on share price, economic conditions, and regulatory requirements [2] - The company retains the right to suspend, amend, or discontinue the program at any time [2] Company Overview - Bio-Techne is a global life sciences company providing tools and bioactive reagents for research and clinical diagnostics [3] - The company's products support scientific investigations into biological processes and disease progression, aiding drug discovery and clinical testing [3] - Bio-Techne has a diverse portfolio with thousands of products [3]